Oslo, April 7, 2010: OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.
Sumatriptan powder in 10mg and 20mg doses administered intranasally using OptiNose's bi-directional delivery device was highly effective in treating a single attack of moderate or severe migraine. The proportion of patients pain-free at two hours was 54% for the 10 mg dose, 57% for 20 mg and 25% for placebo (P< .05). These results compare very favorably with published figures of 26-42% for liquid sumatriptan nasal spray and 35.6% for zolmitriptan nasal spray and higher than the 28% /29% reported for oral triptans. In addition to high efficacy, OptiNose's bi-directional powder delivery eliminates drip-out and reduces the bitter taste associated with conventional nasal triptan products.
The proportion of subjects with relief of headache post-dose was significantly greater than placebo at 60 minutes (10 mg 73% vs. 38%, P< .01; 20 mg 74% vs. 38%, P< .01), 90 minutes (10 mg 78% vs. 41%, P< .01; 20 mg 77% vs. 41%, P< .01) and 120 minutes (10 mg 84% vs. 44%, P< .001; 20 mg 80% vs. 44%, P< .01). The onset of pain relief was much quicker than conventional orally and nasally delivered triptans and similar to subcutaneous injection of sumatriptan despite much lower systemic exposure. Sustained pain-freedom at 48 hours was also high for both doses (10 mg 47%, 20 mg 49%, P < .05). Treatment-related adverse events were rare.
"The World Health Organization places migraine amongst the top 20 of disabling disorders from a global perspective," says Fred Sheftell, M.D., founder and director of the New England Center for Headache in Stamford, CT. "Novel delivery systems that deliver rapid and sustained pain relief with minimal side effects are needed. The resul
|Contact: Helena Djupesland|